ThomasReeveChaunceyMD

Oncology • Seattle, WA

Associate Professor, Medicine, University of Washington School of Medicine

Join to view full profile

Dr. Chauncey is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
Connect with colleagues in the same hospital or clinic.
Read the latest clinical news, personalized to your specialty.

See Dr. Chauncey's full profile

Already have an account?

Office
1660 S Columbian Way
Marrow Transplant Unit (111)
Seattle, WA 98108
Phone+1 206-764-2969

Fax+1 206-764-2851

Education & Training

University of WashingtonFellowship, Hematology and Medical Oncology, 1988 - 1992
University of WashingtonResidency, Internal Medicine, 1985 - 1988
Rush Medical College of Rush University Medical CenterClass of 1985

Certifications & Licensure

WA State Medical License 1986 - 2025
American Board of Internal Medicine Internal Medicine
American Board of Internal Medicine Medical Oncology

Clinical Trials

S9918 PSC 833, Daunorubicin, and Cytarabine in Treating Older Patients With Newly Diagnosed Acute Myeloid Leukemia Start of enrollment: 2000 Feb 01
Completed
Phase 2
Autologous Stem Cell Transplant Followed by Donor Stem Cell Transplant in Treating Patients With Relapsed or Refractory Lymphoma Start of enrollment: 1999 Sep 01
Completed
Phase 1, Phase 2
S0112 Cytarabine and Daunorubicin in Treating Older Patients With Acute Myeloid Leukemia Start of enrollment: 2001 Aug 01
Completed
Phase 2
S0301 Cyclosporine, Daunorubicin, and Cytarabine in Treating Older Patients With Previously Untreated Acute Myeloid Leukemia Start of enrollment: 2004 Jul 01
Completed
Phase 2
Donor Lymphocyte Infusion in Treating Patients With Persistent, Relapsed, or Progressing Cancer After Donor Hematopoietic Cell Transplant Start of enrollment: 2003 May 01
Completed
Phase 1, Phase 2
Tacrolimus and Mycophenolate Mofetil in Preventing Graft-Versus-Host Disease in Patients Who Have Undergone Total-Body Irradiation With or Without Fludarabine Phosphate Followed by Donor Peripheral Blood Stem Cell Transplant for Hematologic Cancer Start of enrollment: 2004 Apr 01
Completed
Phase 2
Pentostatin and Lymphocyte Infusion in Preventing Graft Rejection in Patients Who Have Undergone Donor Stem Cell Transplant Start of enrollment: 2003 May 01
Completed
Phase 2
Fludarabine Phosphate, Radiation Therapy, and Rituximab in Treating Patients Who Are Undergoing Donor Stem Cell Transplant Followed by Rituximab for High-Risk Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma Start of enrollment: 2004 Dec 01
Completed
Phase 2
Melphalan and Amifostine Followed By One or Two Autologous or Syngeneic Stem Cell Transplants and Maintenance Therapy in Treating Patients With Stage II-III Multiple Myeloma Start of enrollment: 2005 Jul 01
Completed
Phase 3
Fludarabine Phosphate and Total Body Irradiation Followed by a Donor Peripheral Stem Cell Transplant in Treating Patients With Myelodysplastic Syndromes or Myeloproliferative Disorders Start of enrollment: 2006 Jan 01
Completed
Phase 2
Umbilical Cord Blood Transplant, Cyclophosphamide, Fludarabine, and Total-Body Irradiation in Treating Patients With Hematologic Disease Start of enrollment: 2005 Nov 18
Active, not recruiting
Phase 2
Donor Umbilical Cord Blood Transplant in Treating Patients With Hematologic Cancer Start of enrollment: 2008 Jun 25
Completed
Phase 2
Graft-Versus-Host Disease Prophylaxis in Treating Patients With Hematologic Malignancies Undergoing Unrelated Donor Peripheral Blood Stem Cell Transplant Start of enrollment: 2010 Nov 01
Completed
Phase 3
Sirolimus, Cyclosporine, and Mycophenolate Mofetil in Preventing Graft-versus-Host Disease in Treating Patients With Blood Cancer Undergoing Donor Peripheral Blood Stem Cell Transplant Start of enrollment: 2010 Dec 01
Completed
Phase 2
Clofarabine and Low-Dose Total-Body Irradiation in Treating Patients With Acute Myeloid Leukemia Undergoing Donor Peripheral Blood Stem Cell Transplant Start of enrollment: 2011 Jan 25
Completed
Phase 2
A Multicenter Access and Distribution Protocol for Unlicensed Cryopreserved Cord Blood Units (CBUs) Start of enrollment: 2011 Oct 01
Recruiting
Join now to see all

Publications & Presentations

PubMed

Neuromuscular electrical stimulation for physical function maintenance during hematopoietic stem cell transplantation: Study protocol.
Lindsey J Anderson, Lauren Paulsen, Gary Miranda, Karen L Syrjala, Solomon A Graf
Plos One. 2024-01-01
2 citations
Examining the impact of age on the prognostic value of ELN-2017 and ELN-2022 acute myeloid leukemia risk stratifications: a report from the SWOG Cancer Research Network.
Christina M Termini, Anna Moseley, Megan Othus, Frederick R Appelbaum, Thomas R Chauncey
Haematologica. 2023-11-01
1 citations
Verification of prognostic expression biomarkers is improved by examining enriched leukemic blasts rather than mononuclear cells from acute myeloid leukemia patients.
Era L Pogosova-Agadjanyan, Xing Hua, Megan Othus, Frederick R Appelbaum, Thomas R Chauncey
Biomarker Research. 2023-03-16

Journal Articles

Long Term Follow-up of Tandem Autologous-Allogeneic Hematopoietic Cell Transplantation for Multiple Myeloma
Parameswaran Hari, Brenda M Sandmaier, Pamela S Becker, Leona Holmberg, Damian J Green, Peter A McSweeney, David G Maloney, Thomas R Chauncey, Haematologica

Abstracts/Posters

Sirolimus Combined with Cyclosporine (CSP) and Mycophenolate Mofetil (MMF) As Graft-Vs-Host Disease (GVHD) Prophylaxis after Nonmyeloablative (NMA) Hematopoietic Cell ...
Thomas R. Chauncey, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019
Development and Performance of Risk Stratification Models for AML Patients Utilizing ELN-2017 Guidelines and Additional Prognostic Factors: A SWOG Report
Thomas R. Chauncey, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019
Ibrutinib in Relapsed or Refractory Transformed Indolent B-Cell Non-Hodgkin Lymphoma: Final Results from a Prospective Phase II Study
Thomas R. Chauncey, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019

Press Mentions

ASH 2016 – Monday, December 5December 5th, 2015
ASH 2016 – Sunday, December 4December 4th, 2015
ASH 2016 – Saturday, December 3December 3rd, 2015